SRBCF (Sirona Biochem) Debt-to-Equity: -0.96 (As of Jul. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Sirona Biochem Debt-to-Equity?

Sirona Biochem SRBCF Debt-to-Equity is -0.96 as of Jul. 2024.

Sirona Biochem's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2024 was $1.12 Mil. Sirona Biochem's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2024 was $1.30 Mil. Sirona Biochem's Total Stockholders Equity for the quarter that ended in Jul. 2024 was $-2.53 Mil. Sirona Biochem's debt to equity for the quarter that ended in Jul. 2024 was -0.96.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sirona Biochem's Debt-to-Equity or its related term are showing as below:

SRBCF's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

Sirona Biochem  (OTCPK:SRBCF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sirona Biochem Debt-to-Equity Related Terms

Sirona Biochem Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Sirona Biochem's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sirona Biochem Debt-to-Equity Chart

Sirona Biochem Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.71 26.08 -8.78 2.19 -0.87

Sirona Biochem Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.25 -0.87 -0.84 -0.89 -0.96

SRBCF vs MTNB, TCRT, QLGN: Debt-to-Equity Comparison

For the Biotechnology subindustry, Sirona Biochem's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sirona Biochem Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sirona Biochem's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sirona Biochem's Debt-to-Equity falls into.


Sirona Biochem Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sirona Biochem's Debt to Equity Ratio for the fiscal year that ended in Oct. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.47 + 1.122) / -1.831
=-0.87

Sirona Biochem's Debt to Equity Ratio for the quarter that ended in Jul. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.124 + 1.296) / -2.526
=-0.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.96 mean?
Sirona Biochem (SRBCF) has a Debt-to-Equity of -0.96 as of Jul. 2024. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sirona Biochem and its competitors.
Is Sirona Biochem's Debt-to-Equity too high?
Sirona Biochem's current Debt-to-Equity is -0.96.
How does Sirona Biochem's Debt-to-Equity compare to MTNB and TCRT?
Sirona Biochem's Debt-to-Equity of -0.96 can be compared against companies in the Biotechnology industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sirona Biochem and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sirona Biochem's current Debt-to-Equity is -0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sirona Biochem stock overvalued right now?
Sirona Biochem (SRBCF) has a current Debt-to-Equity of -0.96. The current Debt-to-Equity is -0.96. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sirona Biochem (SRBCF), the current Debt-to-Equity is -0.96 as of Jul. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sirona Biochem Business Description

Address C/o WeWork, 595 Burrard Street, Vancouver, BC, CAN, V7X 1L4
Sirona Biochem Corp is a development stage biotechnology company. The principal activities of the company are the development of cosmetic and pharmaceutical active ingredients which are licensed to partners in exchange for upfront, milestone, and royalty payments. The company acts as a cosmetic ingredient and drug discovery company with a proprietary technology platform with a specialization in the stabilization of carbohydrate molecules. The company has a business presence in Canada and France.